Deutsche Bank raised the firm’s price target on Elevance Health (ELV) to $332 from $320 and keeps a Hold rating on the shares. The firm says the company’s 2026 outlook “may represent a floor.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $396 from $414 at Guggenheim
- Elevance Health Earnings Call Flags Reset Before Rebound
- Elevance Health sees FY26 operating cash flow ‘at least’ $5.5B
- Elevance Health reports Q4 adjusted EPS $3.33, consensus $3.09
- Elevance Health sees FY26 adjusted EPS ‘at least’ $25.50, consensus $26.80